Theravance Biopharma's total assets for Q4 2025 were $485.57M, an increase of 16.88% from the previous quarter. TBPH total liabilities were $188.85M for the fiscal quarter, a 3.32% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.